


# CORONAVIRUS DISEASE 2019 (COVID-19)

## COVID-19 Vaccine Product and Administration Codes



**Audience:** PBS, HIM, Patient Access, CFO, MGPS, TIS, Revenue Integrity, THAH, THSC, Pharmacy

**Revision Date:** 03/22/2023

**Version :** 29

**COVID-19 Response Team Owner:** Finance

**Date of Last Review:** 03/22/2023

**What's Changed:** On March 14, 2023, the FDA updated the bivalent Pfizer vaccine EUA to approve a booster dose for ages 6 months through 4 years. The AMA released a CPT code for the Pfizer bivalent vaccine booster for this age group.

### Background

On November 10, 2020, The American Medical Association (AMA), in conjunction with CMS, published six new CPT Codes for reporting COVID-19 vaccination products and their respective product specific administration codes. The codes will be effective upon EUA approval from the FDA.

As further vaccinations are developed, the AMA will create a series of new vaccine product and administration codes that are product specific to assist in tracking vaccinations nationally. Creation of product specific codes for administration will allow for tracking of immunization, even if a product codes is not required, due to coding and billing instructions for products provided without cost. CMS will not deny claims that are submitted with the administration codes only.

On December 17, 2020, the AMA in conjunction with CMS, published 3 new CPT codes for reporting the AstraZeneca COVID vaccine product and the respective specific administration codes.

On January 19, 2021, the AMA in conjunction with CMS, published 2 new CPT codes for reporting the Janssen/Johnson & Johnson COVID vaccine product and the respective specific administration code.

On May 4, 2021, the AMA in conjunction with CMS, published 3 new CPT codes for reporting the Novavax COVID vaccine product and the respective administration codes. The codes will be effective upon EUA approval from the FDA.

On June 8, 2021, CMS announced they would provide additional reimbursement for COVID-19 vaccines provided in patient's homes. CMS created a new HCPCS code to report this service. Effective August 24, 2021, CMS has updated the types of homes for which they will provide additional reimbursement for the vaccine.

On July 30, 2021, the AMA released a CPT code for a 3<sup>rd</sup> Pfizer dose for use if the FDA approves a 3<sup>rd</sup> dose.

On August 12, 2021, a 3<sup>rd</sup> dose of Pfizer and Moderna vaccines was EUA approved for immunocompromised people. Effective August 12, 2021 CMS announced coverage and payment amounts for the 3<sup>rd</sup> dose Pfizer and Moderna vaccines. On August 16, 2021, the AMA released a CPT code for a 3<sup>rd</sup> Moderna dose.,

On August 23, 2021, the FDA fully approved the Pfizer vaccine for individuals 16 years and older. The vaccine will be marketed as Comirnaty.

On September 3, 2021, the AMA pro-actively released seven new Pfizer and Moderna vaccine and administration codes to reflect future new formulations and doses.

On October 6, 2021, the AMA pro-actively released three new Pfizer vaccine and administration codes for the future pediatric vaccine dose.

On October 20, 2021, the FDA EUA approved booster dose of the Moderna and J&J COVID-19 vaccines. A booster dose administration code for Moderna was published in September. The AMA has not yet published the J&J booster code administration code. On October 28, 2021 the AMA released a new administration code for the J&J booster dose.

On November 2, 2021, the Pfizer pediatric COVID-19 vaccine was EUA approved for ages 5-11.

On January 3, 2022, Pfizer pediatric vaccine 3<sup>rd</sup> dose was EUA approved. On January 12, 2022, the AMA released a 3<sup>rd</sup> dose administration code.

On January 31, 2022, the FDA fully approved the Moderna vaccine. Pfizer Tris-sucrose adult codes given a January 3, 2022 effective date.

On February 1, 2022, the AMA released HCPCS codes for Pfizer's pediatric vaccine for children ages 6 months to 5 years.

On March 7, 2022, the AMA released new vaccine and administration HCPCS codes for a new dose-specific Moderna booster packaging.

On March 29, 2022, the FDA updated Moderna's COVID vaccine EUA approval letter to include the new booster specific packaging and the second booster dose.

On April 26, 2022, the AMA released new vaccine and administration CPT codes for Sanofi Pasteur booster vaccine and a new administration code for Pfizer pediatric booster vaccine. Both vaccines are not yet EUA approved.

On May 5, 2022 the U.S. Food and Drug Administration has limited the authorized use of the Johnson & Johnson, Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Johnson & Johnson, Janssen COVID-19 Vaccine because they would otherwise not receive a COVID-19 vaccine.

On May 17, 2022, the FDA EUA was updated to cover a booster dose for Pfizer vaccine for ages 5-11.

On June 7, 2022, the AMA released a new vaccine administration CPT code for Pfizer 3<sup>rd</sup> dose vaccine for ages 6 months through 4 years. In late May, the AMA released Moderna vaccine and administration codes for ages 6 months through 5 years.

On June 17, 2022, the FDA EUA approved the Pfizer and Moderna vaccines for children down to 6 months old.

On July 6, 2022, the AMA related four new Moderna vaccine administration codes 0091A, 0092A, 0093A, 0113A and updated the description of CPT 0094A. The applicable age group for existing Moderna vaccines was also revised.

On July 8, 2022, the FDA fully approved the Pfizer COVID-19 vaccine for ages 12-15.

On July 13, 2022, the FDA EUA approved the Novavax COVID-19 vaccine for ages 18 and older.

On August 19, 2022, the FDA EUA approved the Novavax COVID-19 vaccine for ages 12-17. No information yet on whether AMA will create specific administration codes.

On August 31, 2022, the FDA EUA approved the new bivalent Pfizer and Moderna COVID-19 vaccines and no longer authorizes the monovalent (original) vaccines for booster doses. On September 1, 2022, the AMA released CPT codes for these vaccines.

On October 10, 2022, the AMA released a booster dose code for Novavax for use when that booster dose is EUA approved.

On October 12, 2022 the FDA approved emergency use authorization for the bivalent COVID-19 booster vaccines for ages 5-11 for Pfizer and 6-11 for Moderna. The monovalent Pfizer and Moderna vaccines are no longer EUA approved as booster doses for this age group.

On October 19, 2022 the FDA EUA approved the Novavax booster dose.

On December 8, 2022, the FDA EUA approved the bivalent Moderna and Pfizer vaccines for ages 6 months through 5 years. In November 2022, the AMA released CPT codes for the Moderna bivalent vaccine for this age group. On December 9, 2022, the AMA released CPT codes for the Pfizer bivalent vaccine for this age group.

On March 14, 2023, the FDA EUA approved the bivalent Pfizer vaccine booster dose for ages 6 months through 4 years. On March 17, 2023, the AMA released a CPT code for this booster dose.

The AMA CPT Editorial panel also created a new Appendix Q, which will list the CPT codes for the applicable manufacturer specific product and its corresponding administration codes, NDC code and dosing schedule.

<https://www.ama-assn.org/system/files/2020-11/covid-19-immunizations-appendix-q-table.pdf>

## Vaccine/Immunization Product

For reporting Immunization product:

- **91300:** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use – FOR **PFIZER BioNTech Comirnaty** COVID-19 Vaccine
  - Fully FDA approved on 8/23/2021 for ages =>16
  - Fully FDA approved on 07/08/2022 for ages 12-15
- **91305:** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use – FOR **PFIZER Tris-sucrose** COVID-19 Vaccine
  - Fully FDA approves for ages =>16 in 2021
  - Fully FDA approved on 07/08/2022 for ages 12-15
- **91307:** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use – FOR **PFIZER Tris-sucrose** COVID-19 vaccine for pediatric ages 5-11
  - EUA approved on November 2, 2021
- **91308:** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use – FOR **PFIZER Tris-sucrose** COVID-19 vaccine for pediatric ages 6 months through 4 years
  - EUA approved on June 17, 2022
- **91312:** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use – FOR **PFIZER Tris-sucrose Bivalent** COVID-19 **Booster** Vaccine for ages 12 and older
  - EUA approved on August 31, 2022
- **91315:** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use– FOR **PFIZER Tris-sucrose Bivalent** COVID-19 **Booster** Vaccine for ages 5-11
  - EUA approved on October 12, 2022

- **91317:** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use – FOR **PFIZER Tris-sucrose Bivalent COVID-19 vaccine** for ages 6 months through 4 years
  - EUA Approved December 8, 2022
- **91301:** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, **100 mcg/0.5mL dosage**, for intramuscular use – FOR **MODERNA COVID -19 Vaccine**
  - Fully FDA approved January 31, 2022
  - As of June 17, 2022 these codes are for ages 12 and older
- **91306:** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, **50 mcg/0.25 mL dosage**, for intramuscular use - FOR **MODERNA COVID-19 Vaccine Booster**
  - EUA approved October 20,2021,
- **91309:** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use – FOR **MODERNA COVID-19 Vaccine Booster**
  - Use for Moderna booster from new dose-specific packaging
  - Use with administration code 0094A
  - EUA approved March 29, 2022
- **91311:** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative-free, 25 mcg/0.25 mL dosage, for intramuscular use – FOR **MODERNA COVID-19 Vaccine** for pediatric ages 6 months through 5 years
  - EUA approved on June 17, 2022
- **91313:** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use – FOR **MODERNA COVID-19 Bivalent Vaccine Booster** for 12 years and older
  - EUA approved on August 31, 2022 for ages 18 and older
  - EUA approved on October 12, 2022 for ages 12-17
- **91314:** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use – FOR **MODERNA COVID-19 Bivalent Vaccine Booster** for ages 6-11
  - EUA approved on October 12, 2022
- **91316:** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use – FOR **MODERNA COVID-19 Bivalent Vaccine Booster** for ages 6 months through 5 years
  - EUA approved December 8. 2022
- **91302:** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10<sup>10</sup> viral particles/0.5mL dosage, for intramuscular use – FOR **AstraZeneca COVID-19 Vaccine**
  - Not yet EUA or fully FDA approved
- **91303:** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10<sup>10</sup> viral particles/0.5mL dosage, for intramuscular use – FOR **Janssen/J&J COVID-19 Vaccine**

- **91304:** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use – FOR **Novavax** COVID-19 Vaccine
  - EUA approved on July 13, 2022 for 18 and older.
  - EUA approved on August 19, 2022 for ages 12-17
- **91310:** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use – FOR **Sanofi Pasteur** COVID-19 Vaccine
  - Not yet EUA or fully FDA approved

## Vaccine/Immunization Administration

For reporting the Administration of the product, the following codes have been developed. Per the CPT Assistant article, these codes include any counseling if performed. Per the CMS FAQ updated February 19, 2021, question 23 of the BB. Drugs and Vaccines Section, revenue code 771 should be used with the administration code.

- **0001A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose – FOR **PFIZER BioNTech Comirnaty** COVID-19 Vaccine Administration – 1<sup>st</sup> dose
- **0002A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose. FOR **PFIZER BioNTech Comirnaty** COVID-19 Vaccine Administration – 2<sup>nd</sup> dose.
- **0003A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose. FOR **PFIZER BioNTech Comirnaty** COVID-19 Vaccine Administration – 3<sup>rd</sup> dose.
  - EUA approved August 12, 2021 for immunocompromised people.
- **0004A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose. FOR **PFIZER BioNTech Comirnaty** COVID-19 Vaccine Administration – booster dose.
  - EUA approved on September 22, 2021
- **0051A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose. FOR **PFIZER tris-sucrose** COVID-19 Vaccine Administration – first dose.
  - EUA approved
- **0052A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; second dose. FOR **PFIZER tris-sucrose** COVID-19 Vaccine Administration – second dose.
  - EUA approved
- **0053A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; third dose. FOR **PFIZER tris-sucrose** COVID-19 Vaccine Administration – third dose.

- EUA approved
- **0054A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; booster dose. FOR **PFIZER tris-sucrose** COVID-19 Vaccine Administration – booster dose.
  - EUA approved
- **0071A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose – FOR **PFIZER Tris-sucrose** COVID-19 vaccine administration for pediatric ages 5-11
  - EUA approved on November 2, 2021
- **0072A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose - FOR **PFIZER Tris-sucrose** COVID-19 vaccine administration for pediatric ages 5-11
  - EUA approved on November 2, 2021
- **0073A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose – FOR **PFIZER Tris-sucrose** COVID-19 vaccine administration for pediatric ages 5-11
  - EUA approved on January 3, 2022
- **0074A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose – FOR **PFIZER Tris-sucrose** COVID-19 vaccine administration for pediatric ages 5-11
  - Use with vaccine code 91307
  - EUA approved on May 17, 2022
- **0081A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose – FOR **PFIZER Tris-sucrose** COVID-19 vaccine administration for pediatric ages 6 months through 4 years
  - EUA approved on June 17, 2022
- **0082A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose – FOR **PFIZER Tris-sucrose** COVID-19 vaccine administration for pediatric ages 6 months through 4 years
  - EUA approved on June 17, 2022
- **0083A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose – FOR **PFIZER Tris-sucrose** COVID-19 vaccine administration for pediatric ages 6 months through 4 years
  - EUA approved on June 17, 2022
- **0173A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, **third dose** – FOR **PFIZER Tris-sucrose Bivalent** COVID-19 vaccine for ages 6 months through 4 years
  - EUA approved December 8, 2022

- **0174A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, **booster dose – FOR PFIZER Tris-sucrose Bivalent COVID-19 vaccine for ages 6 months through 4 years**
  - EUA approved on March 14, 2023
- **0124A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, booster dose – FOR **PFIZER Tris-sucrose Bivalent COVID-19 Booster Vaccine for ages 12 and older**
  - EUA approved on August 31, 2022
- **0154A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose – FOR **PFIZER Tris-sucrose Bivalent COVID-19 Booster Vaccine for ages 5-11**
  - EUA approved on October 12, 2022
- **0011A:** Immunization administration by intramuscular injection of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose – FOR **MODERNA COVID -19 Vaccine Administration – 1<sup>st</sup> Dose**
  - As of June 17, 2022 these codes are for ages 12 and older
- **0012A:** Immunization administration by intramuscular injection of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose. – FOR **MODERNA COVID -19 Vaccine – 2<sup>nd</sup> Dose**
  - As of June 17, 2022 these codes are for ages 12 and older
- **0013A:** Immunization administration by intramuscular injection of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; third dose. – FOR **MODERNA COVID -19 Vaccine – 3<sup>rd</sup> Dose**
  - EUA approved August 12, 2021 for immunocompromised people.
  - As of June 17, 2022 these codes are for ages 12 and older
- **0064A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose. – FOR **MODERNA COVID-19 Vaccine Administration 50mcg/0.25ml dose booster.**
  - EUA approved October 20,2021
- **0091A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; first dose when administered **to individuals 6 through 11 years – FOR MODERNA COVID-19 Vaccine Administration – 1<sup>st</sup> dose**
  - EUA approved June 17, 2022
  - Use with code 91309
- **0092A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; second dose when administered **to individuals 6 through 11 years – FOR MODERNA COVID-19 Vaccine Administration – 2<sup>nd</sup> dose**
  - EUA approved June 17, 2022
  - Use with code 91309
- **0093A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; third dose when administered **to individuals 6 through 11 years – FOR MODERNA COVID-19 Vaccine Administration – 3<sup>rd</sup> dose**

- EUA approved June 17, 2022
- Use with code 91309
- **0094A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose when administered to **individuals 18 years and over**– FOR **MODERNA COVID-19 Vaccine Administration 50mcg/0.5ml dose booster**.
  - EUA approved March 29, 2022
  - Use with code 91309
- **0111A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; first dose – FOR **MODERNA COVID-19 Vaccine Administration 1<sup>st</sup> Dose** for pediatric ages 6 months through 5 years.
  - EUA approved on June 17, 2022
- **0112A:** : Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; second dose – FOR **MODERNA COVID-19 Vaccine Administration 2<sup>nd</sup> Dose** for pediatric ages 6 months through 5 years.
  - EUA approved on June 17, 2022
- **0113A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; third dose – FOR **MODERNA COVID-19 Vaccine Administration 3<sup>rd</sup> Dose** for immunocompromised pediatric ages 6 months through 5 years.
  - EUA approved on June 17, 2022
- **0134A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, booster dose – FOR **MODERNA COVID-19 Bivalent Vaccine Booster Administration** for 12 years and older
  - EUA approved on August 31, 2022 for ages 18 and older
  - EUA approved on October 12, 2022 for ages 12-17
- **0144A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, booster dose – FOR **MODERNA COVID-19 Bivalent Vaccine Booster Administration** for ages 6-11
  - EUA approved on October 12, 2022
- **0164A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, booster dose – FOR **MODERNA COVID-19 Bivalent Vaccine Booster Administration** for ages 6 months through 5 years
  - EUA approved December 8, 2022
- **0021A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10<sup>10</sup> viral particles/0.5mL dosage; first dose. FOR **AstraZeneca COVID-19 Vaccine Administration – 1<sup>st</sup> Dose**
  - Not yet EUA or fully FDA approved
- **0022A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10<sup>10</sup> viral particles/0.5mL dosage; second dose. FOR **AstraZeneca COVID-19 Vaccine Administration – 2<sup>nd</sup> Dose**

- Not yet EUA or fully FDA approved
- **0031A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10<sup>10</sup> viral particles/0.5mL dosage, single dose. FOR **Janssen/J&J** COVID-19 Vaccine – single dose
- **0034A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10<sup>10</sup> viral particles/0.5mL dosage, booster dose. FOR **Janssen/J&J** COVID-19 Vaccine – booster dose
  - ~~EUA approved October 20, 2021~~
  - EUA limited approval to adults aged 18 and over; who elect Janssen or if other authorized approved vaccines are not available or are not clinically appropriate on May 5, 2022.
- **0041A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; first dose. – FOR **Novavax** COVID-19 Vaccine – 1<sup>st</sup> dose
  - EUA approved on July 13, 2022 for 18 and older
  - EUA approved on August 19, 2022 for ages 12-17
- **0042A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; second dose. – FOR **Novavax** COVID-19 Vaccine – 2<sup>nd</sup> dose
  - EUA approved on July 13, 2022 for 18 and older
  - EUA approved on August 19, 2022 for ages 12-17
- **0044A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; second dose. – FOR **Novavax** COVID-19 Vaccine booster dose ages 18 and older
  - EUA approved on October 19, 2022
- **0104A:** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion; booster dose – FOR **Sanofi Pasteur** COVID-19 Vaccine
  - Booster dose only, can be used after any of the initial vaccine doses/series
  - Not yet EUA or fully FDA approved

## Information by Vaccine

Manufacturer	Vaccine Description	Vaccine Product Code*	Vaccine/ Immunization Admin Code	FDA Information	Comments
<b>Pfizer Comirnaty</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use	91300	0001A (1 <sup>st</sup> dose)  0002A (2 <sup>nd</sup> dose)  0003A (3 <sup>rd</sup> dose)  <del>0004A (booster dose)</del> as of 08/30/22	1 <sup>st</sup> and 2 <sup>nd</sup> Dose FDA approved on 8/23/2021 for ages =>16  3 <sup>rd</sup> and booster doses EUA approved.  As of 08/30/22 no longer authorized as booster dose.  1 <sup>st</sup> and 2 <sup>nd</sup> Dose FDA approved on 07/08/2022 for ages 12-15	Note: this is the purple cap
<b>Pfizer</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, <b>30 mcg/0.3 mL dosage, tris-sucrose formulation</b> , for intramuscular use	91305	0051A (1 <sup>st</sup> dose)  0052A (2 <sup>nd</sup> dose)  0053A (3 <sup>rd</sup> dose)  <del>0054A (booster dose)</del> as of 08/30/22	1 <sup>st</sup> and 2 <sup>nd</sup> Dose FDA approved  3 <sup>rd</sup> and booster doses EUA approved As of 08/30/22 no longer authorized as booster dose.  1 <sup>st</sup> and 2 <sup>nd</sup> Dose FDA approved on 07/08/2022 for ages 12-15	Codes effective date 01/03/2022 Note: this is the gray cap
<b>Pfizer</b> For ages 5-11	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, <b>10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation</b> , for intramuscular use	91307	0071A (1 <sup>st</sup> dose)  0072A (2 <sup>nd</sup> dose)  0073A (3 <sup>rd</sup> dose)	1 <sup>st</sup> and 2 <sup>nd</sup> dose EUA approved on 11/02/21  3 <sup>rd</sup> dose EUA approved on 01/03/22  Booster dose EUA approved on 05/17/22	Note: this is the orange cap for booster dose

			0074A (booster dose)		
<b>Pfizer</b> For ages 6 months through 4 years	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	91308	0081A (1 <sup>st</sup> dose)  0082A (2 <sup>nd</sup> dose)  <del>0083A (3<sup>rd</sup> dose)</del>	EUA approved on 06/17/22  As of 12/08/2022, the monovalent vaccine is no longer approved as the 3 <sup>rd</sup> dose. The bivalent vaccine should be used.	Three dose series Note: this is the maroon cap
<b>Pfizer Bivalent</b> For ages 6 months through 4 years	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	91317	0173A (3 <sup>rd</sup> dose)  0174A (booster dose)	EUA approved on 12/08/2022  Booster dose EUA approved on 03/14/2023	Note: This is maroon cap with maroon border.
<b>Pfizer Bivalent Booster</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	91312	0124A	EUA approved on 08/31/2022 for ages 12 and older	Note: This is gray cap with gray border.
<b>Pfizer Bivalent Booster</b> For ages 5-11	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	91315	0154A	EUA approved on 10/12/2022	Note: This is orange cap with orange border.
<b>Moderna Spikevax</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free,	91301	0011A (1 <sup>st</sup> dose)  0012A (2 <sup>nd</sup> dose)	For ages 18 and older, 1 <sup>st</sup> and 2 <sup>nd</sup> dose Fully FDA approved 01/31/2022  As of 06/17/22 these codes are for ages 12	Note: this is the Red cap/Light Blue border

	100 mcg/0.5mL dosage, for intramuscular use		0013A (3 <sup>rd</sup> dose)	and older EUA approved  3 <sup>rd</sup> dose EUA approved	
<b>Moderna</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use	91306	<del>0064A (booster dose)</del> as of 08/30/22	Booster dose EUA approved 10/20/21 Booster pulled from initial dose vials As of 08/30/22 no longer authorized as booster dose.	Note: this is the Red cap/Light Blue label border
<b>Moderna</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	91309	0091A (1 <sup>st</sup> dose ages 6-11)  0092A (2 <sup>nd</sup> dose ages 6-11)  0093A (3 <sup>rd</sup> dose ages 6-11)  0094A ( <del>booster dose for 18 and older</del> ) as of 08/30/22	EUA approved 03/29/22 booster ages 18 and older As of 08/30/22 no longer authorized as booster dose.  EUA approved for ages 6-11 06/17/2022	Note: this is the Dark blue cap/Purple label border
<b>Moderna</b>  For 6 months through 5 years	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative-free, 25 mcg/0.25 mL dosage, for intramuscular use	91311	0111A (1 <sup>st</sup> dose)  0112A (2 <sup>nd</sup> dose)  0113A (3 <sup>rd</sup> dose)	EUA approved on 06/17/22	Two dose series Note: this is the Dark blue cap/Magenta label border
<b>Moderna Bivalent Booster</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50	91313	0134A	EUA approved on 08/31/2022 for ages 18 & older	Note: this is blue cap with gray border.

	mcg/0.5 mL dosage, for intramuscular use			EUA approved on 10/12/2022 for ages 12-17	
<b>Moderna Bivalent Booster</b> <b>For ages 6-11</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular	91314	0144A	EUA approved on 10/12/2022	Note: this is blue cap with gray border.
<b>Moderna Bivalent Booster</b> <b>For ages 6 months – 5 years</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use	91316	0164A	EUA approved on 12/8/2022	Note: this is dark pink cap with yellow border
<b>Janssen/Johnson &amp; Johnson</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 <sup>10</sup> viral particles/0.5mL dosage, for intramuscular use	91303	0031A (single dose)  0034A (booster dose)	EUA Approval limited to adults => 18 years, by choice or availability secondary to safety concerns	
<b>Novavax</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use	91304	0041A (1 <sup>st</sup> dose)  0042A (2 <sup>nd</sup> dose)  0044A (booster dose)	EUA approved on 07/13/22 for 18 and older  EUA approved on 08/19/22 for ages 12-17  Booster dose EUA approved on 10/19/22 for ages 18 and older.	
<b>AstraZeneca</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 <sup>10</sup> viral particles/0.5mL	91302	0021A (1 <sup>st</sup> dose)  0022A (2 <sup>nd</sup> dose)	Not EUA or fully FDA approved yet	

	dosage, for intramuscular use				
<b>Sanofi Pasteur</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use	91310	0104A (booster dose only)	Not EUA or FDA approved yet	

\*Product reimbursement will be 95% Average Wholesale Price, which has not been determined, to date.

\*\*Geographic adjustments to be applied.

### Medicare Payment and Trinity Health Standard Recommended Price

Prior to March 15, 2021, CMS reimbursed \$16.94 for the first dose and \$28.39 for the second dose. On/after March 15, 2021, CMS updated reimbursement to \$40.00 for each dose.

Prior to March 15, 2021, the Trinity Health recommended standard price was \$64 for first dose (3.75x the Medicare payment + geographic adjustment where applicable) and \$106 for the second dose. After CMS revised the reimbursement amount on March 15, 2021, the Trinity Health recommended standard price was changed to \$85 per dose.

### Billing & Coding Guidance

Per the CMS FAQ updated February 19, 2021, question 27 of the BB. Drugs and Vaccines Section, CMS confirms that an order is not required for the COVID-19 vaccine.

CMS states that when the vaccine product is provided free of charge by the government, the product should not be billed, only the administration would be billed.

- When the vaccine product is provided free of charge, set CDM price to \$0.00 so the product is charged and is on the account but does not go to the claim.

For UB billing, there are up to three condition codes required for billing of the COVID vaccines.

- Because the vaccines are EUA approved, condition code 91 is also required for billing, effective with claims billed on or after February 1, 2021.
- Condition code A6 is needed for these vaccine accounts. (CMS confirmed in FAQ updated February 19, 2021)

Claims for Medicare Advantage Plan should be submitted to Original Medicare for all patients enrolled in Medicare Advantage in 2020 and 2021.

- Condition code 78 is needed when billing for an MA beneficiary to Medicare FFS.

CMS will allow roster billing for this therapy if provided by entities that do roster billing.

All Claims should contain the diagnosis code Z23, encounter for immunization, unless payer specific guidance directs otherwise. (CMS confirmed in FAQ updated February 19, 2021)

Condition code DR is not required on the COVID-19 vaccine claims.

There will be no cost-sharing for Medicare beneficiaries and likely all payers.

## Billing & Coding Guidance for COVID-19 Vaccine Provided in Patient's Home

As of June 8, 2021, CMS will provide additional reimbursement for COVID-19 vaccines provided to patients at home. CMS created HCPCS code M0201 (COVID-19 vaccine home admin) is used to identify these vaccines when provided in homes. This code is billed in addition to the vaccine administration code. The presence of M0201 will allow an additional payment of \$35.50. For a two-shot dose, the payment will be allowed for each dose provided at a patient's home. CMS has created specific guidelines related to the additional payment.

The additional payment is allowed when either:

- Patient has difficulty leaving home
  - They have a condition, due to an illness or injury, that restricts their ability to leave home without a supportive device or help from a paid or unpaid caregiver
  - They have a condition that makes them more susceptible to contracting a pandemic disease like COVID-19
  - They are generally unable to leave the home, and if they do leave home it requires a considerable and taxing effort
- The patient is hard-to-reach because they have a disability or face clinical, socioeconomic, or geographical barriers to getting a COVID-19 vaccine in settings other than their home. These patients face challenges that significantly reduce their ability to get vaccinated outside the home, such as challenges with transportation, communication, or caregiving.

The vaccine provider or physician does not need to certify that the Medicare patient is homebound, but documentation in the patient's medical record must include their clinical status or the barriers they face to getting the vaccine outside the home.

The following are examples of types of locations that would qualify as Medicare patient's home:

- A private residence
- Temporary lodging (for example, a hotel or motel, campground, hostel, or homeless shelter)
- An apartment in an apartment complex or a unit in an assisted living facility or group home
- A Medicare patient's home that's made provider-based to a hospital during the COVID-19 public health emergency
- Effective August 24, 2021, Communal spaces of a multi-unit living arrangement
- Effective August 24, 2021, assisted living facilities participating in the CDC's Pharmacy Partnership for Long-Term Care Program when their residents are vaccinated through this program

The following locations don't qualify as a home for the additional payment amount:

- ~~Communal spaces of a multi-unit living arrangement~~ (removed from this section effective with the August 24<sup>th</sup> updates)
- Hospitals, Medicare skilled nursing facilities (SNFs), and Medicaid nursing facilities, regardless of whether they are the patient's permanent residence
- ~~Assisted living facilities participating in the CDC's Pharmacy Partnership for Long-Term Care Program when their residents are vaccinated through this program~~ (removed from this section effective with the August 24<sup>th</sup> updates)

Medicare only pays the additional amount if the sole purpose of the visit is to administer a COVID-19 vaccine. Medicare doesn't pay the additional amount if another Medicare service is provided in the same home on the same date.

If you administer the COVID-19 vaccine to more than 1 Medicare patient in a single home in the same multi-unit or communal living arrangement on the same day, Medicare pays:

- Approximately \$40 to administer each dose of the COVID-19 vaccine
  - including additional doses administered on or after August 12, 2021
- For dates of service between June 8, 2021 and August 24, 2021, Medicare pays the additional payment amount of approximately \$35 only once per date of service in that home regardless of how many Medicare patients receive the vaccine
- Effective on August 24, 2021, Medicare pays the additional payment amount (approximately \$35 per dose administered), for up to a maximum of 5 vaccine administration services per home unit or communal space within a single group living location; but only when fewer than 10 Medicare patients receive a COVID-19 vaccine dose on the same day at the same group living location
- Refer to the CMS website for detailed examples: <https://www.cms.gov/medicare/covid-19/medicare-billing-covid-19-vaccine-shot-administration>

NOTE: CMS has additional guidance for roster billing. See CMS References if roster billing.

## References

- AMA Code Release Communication November 10, 2020: <https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-vaccine-and-immunization-codes>,
- AMA Code Release Communication December 17, 2020 : <https://www.ama-assn.org/press-center/press-releases/ama-announces-additional-cpt-codes-covid-19-vaccines>
- AMA Code Release Communication January 19, 2021: <https://www.ama-assn.org/press-center/press-releases/ama-announces-update-covid-19-vaccine-cpt-codes>
- AMA Code Release Communication July 30, 2021: <https://www.ama-assn.org/press-center/press-releases/ama-announces-update-covid-19-vaccine-cpt-codes-1>
- AMA Code Release Communication February 1, 2022: [AMA announces CPT update for pediatric COVID-19 vaccine candidate | American Medical Association \(ama-assn.org\)](#)
- AMA COVID-19 Vaccine Code List August 31, 2022: [Coronavirus \(SARS-CoV-2\) vaccine: Long descriptors \(ama-assn.org\)](#)
- **AMA Code Release Communication March 18, 2023:** [COVID-19 CPT vaccine and immunization codes | American Medical Association \(ama-assn.org\)](#)
- AMA COVID-19 Coding: [COVID-19 CPT coding and guidance | American Medical Association \(ama-assn.org\)](#); [Coronavirus \(SARS-CoV-2\) vaccine: Long descriptors \(ama-assn.org\)](#)
- Pfizer FDA Approval: [FDA Approves First COVID-19 Vaccine | FDA](#); [Pfizer-BioNTech COVID-19 vaccine emergency use authorization \(PDF\)](#); [Pfizer-BioNTech COVID-19 Vaccine EUA LOA reissued June 17, 2022 \(fda.gov\)](#); [Bivalent Vaccine Update: Recipients and Caregivers 12 years of age and older 08312022 \(fda.gov\)](#); [Coronavirus \(COVID-19\) Update: FDA Authorizes Moderna and Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose in Younger Age Groups | FDA](#); **[Coronavirus \(COVID-19\) Update: FDA Authorizes Bivalent Pfizer-BioNTech COVID-19 Vaccine as Booster Dose for Certain Children 6 Months through 4 Years of Age | FDA](#)**
- Moderna FDA Approval: [Coronavirus \(COVID-19\) Update: FDA Takes Key Action by Approving Second COVID-19 Vaccine | FDA](#); [Moderna COVID-19 Vaccine EUA Letter of Authorization 03292022 \(fda.gov\)](#); [Moderna COVID-19 Vaccine EUA Letter of Authorization 03292022 \(fda.gov\)](#); [Bivalent Vaccine Update: Moderna COVID-19 Vaccine EUA Fact Sheet for Recipients and Caregivers 08312022 \(fda.gov\)](#); [Coronavirus \(COVID-19\) Update: FDA Authorizes Moderna and Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose in Younger Age Groups | FDA](#)
- Moderna Vaccine Vial FDA Information: [Moderna COVID-19 Vaccine Wallchart 06172022 \(fda.gov\)](#)
- Pfizer/Moderna EUA Approval: [Coronavirus \(COVID-19\) Update: FDA Authorizes Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children Down to 6 Months of Age | FDA](#); [Recipients and Caregivers 12 years of age and older 07082022 \(fda.gov\)](#); [Coronavirus \(COVID-19\) Update: FDA Authorizes Updated \(Bivalent\) COVID-19 Vaccines for Children Down to 6 Months of Age | FDA](#)
- Novavax EUA Approval: [Coronavirus \(COVID-19\) Update: FDA Authorizes Emergency Use of Novavax COVID-19 Vaccine, Adjuvanted | FDA](#); [Novavax Letter of Authorization 08192022 \(fda.gov\)](#); [U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster for Adults - Oct 19, 2022](#)
- COVID Toolkit for Insurers and MA Plans: <https://www.cms.gov/files/document/COVID-19-toolkit-issuers-MA-plans.pdf>,
- COVID Vaccine CPT Assistant: <https://www.ama-assn.org/system/files/2020-11/cpt-assistant-guide-covid-vaccine-coding-2020.pdf>

- AMA COVID CPT Assistant September 2021: <https://www.ama-assn.org/system/files/cpt-assistant-guide-coronavirus-september-2021.pdf>
- AMA CPT Assistant October 2021 : [CPT Assistant guide: Coronavirus \(SARS-CoV-2\); October 2021 \(ama-assn.org\)](#)
- AMA CPT Assistant March 7, 2022: [CPT Assistant guide: Coronavirus \(SARS-CoV-2\); March 2022 \(ama-assn.org\)](#)
- AMA CPT Assistant April 26, 2022: [CPT Assistant guide: Coronavirus \(SARS-CoV-2\); April 2022 \(ama-assn.org\)](#)
- AMA CPT Assistant May 2022: [CPT Assistant guide: Coronavirus \(SARS-CoV-2\); May 2022 \(ama-assn.org\)](#)
- AMA CPT Assistant June 7, 2022: [CPT Assistant guide: Coronavirus \(SARS-CoV-2\); June 2022 \(ama-assn.org\)](#)
- AMA CPT Assistant July 6, 2022: [CPT Assistant guide: Coronavirus \(SARS-CoV-2\); July 2022 \(ama-assn.org\)](#)
- AMA CPT Assistant October 12, 2022: [CPT Assistant guide: Coronavirus \(SARS-CoV-2\); October 2022 \(ama-assn.org\)](#)
- AMA CPT Assistant November 16, 2022: [CPT Assistant guide: Coronavirus \(SARS-CoV-2\); November 2022 \(ama-assn.org\)](#)
- AMA CPT Assistant December 9, 2022: [CPT Assistant guide: Coronavirus \(SARS-CoV-2\); December 2022 \(ama-assn.org\)](#)
- COVID Vaccine & Monoclonal Antibody Billing Guidance: <https://www.cms.gov/files/document/covid-medicare-mono-clonal-antibody-infusion-program-instruction.pdf>
- CMS Medicaid COVID-19 Vaccine Guidance/Toolkit: <https://www.medicaid.gov/state-resource-center/downloads/covid-19-vaccine-toolkit.pdf>
- CMS COVID-19 Vaccine codes, payment, effective dates: [COVID-19 Vaccines and Monoclonal Antibodies | CMS](#)
- First Coast COVID-19 Vaccine Billing: [COVID-19 vaccine and monoclonal antibody billing for Part A providers \(fcso.com\)](#)
- NGS COVID-19 Vaccine Billing: [Medicare Part B Billing for the COVID-19 Vaccine and Monoclonal Antibody - News and Alerts \(ngsmedicare.com\)](#)
- CMS Medicare COVID-19 Vaccine Shot Payment: <https://www.cms.gov/medicare/covid-19/medicare-covid-19-vaccine-shot-payment>
- CMS Medicare COVID-19 Vaccine Shot Administration: <https://www.cms.gov/medicare/covid-19/medicare-billing-covid-19-vaccine-shot-administration>
- Johnson & Johnson (Janssen) FDA EUA limitation: [Janssen COVID-19 Vaccine EUA Fact Sheet for Recipients and Caregivers \(fda.gov\)](#)
- CDC COVID-19 Vaccine Infographic: [COVID-19 Vaccine Interim COVID-19 Immunization Schedule for 6 Months of Age and Older \(cdc.gov\)](#)

We appreciate your support as we work Together to ensure the safety of our patients, and community at large